Phase One, a leading developer of digital imaging technologies, has announced the successful launch and orbital deployment of an imaging sensor based on the Phase One iXM Series 150MP frame camera.
Equillium, Inc. underwent a pipeline reset after its lead asset failed, pivoting to GI diseases with EQ504 as the new ...
IDRX-42 continues to demonstrate promising anti-tumor activity with a 29% ORR across all patients (median four prior lines of therapy) and a 53% objective response rate (ORR) in second-line patients ...
Vigil Neuroscience reported positive Phase 1 trial results for VG-3927 and plans a Phase 2 trial in Q3 2025. Vigil Neuroscience, Inc. announced promising outcomes from a Phase 1 clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results